DOCKET NO.: RTS-0242US.P1

PATENT

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: C. Frank Bennett

Serial No.:

10/672,866

Group Art Unit: 1635

Filed:

**September 26, 2003** 

**Examiner: Kimberly Chong** 

For:

Antisense Modulation of Superoxide Dismutase 1, Soluble

aura Eames hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or being facsimile transmitted to the USPTO, on the date indicated helow.

Commissioner for Patents Mail Stop: Fee Amendment PO Box 1450

Alexandria, VA 22313-1450

#### AMENDMENT AND REQUEST FOR RECONSIDERATION

Dear Examiner Chong:

This is in response to the Office Action dated May 3, 2005 setting a three (3) month period for response. The Applicants hereby request an extension of one (1) month in time for response.

Applicants respectfully request that the following amendments be entered, without prejudice:

Amendments to the Specification begin on page 2.

Amendments to the Claims begin on page 3.

Amendments to the Sequence Listing begin on page 5.

Remarks begin on page 6.

#### **DOCKET NO.: RTS-0242US.P1**

**PATENT** 

This version of the paragraph on page 127, line 29 to page 128, line 13 will replace all prior versions of the paragraph in the specification:

In accordance with the present invention, a series of nucleic acid duplexes comprising the antisense compounds of the present invention and their complements can be designed to target superoxide dismutase-1, soluble. The nucleobase sequence of the antisense strand of the duplex comprises at least a portion of an oligonucleotide to superoxide dismutase-1, soluble as described herein. The ends of the strands may be modified by the addition of one or more natural or modified nucleobases to form an overhang. The sense strand of the dsRNA is then designed and synthesized as the complement of the antisense strand and may also contain modifications or additions to either terminus. For example, in one embodiment, both strands of the dsRNA duplex would be complementary over the central nucleobases, each having overhangs at one or both termini. For example, a duplex comprising an antisense strand having the sequence CGAGAGGCGGACGGGACCG and having a two-nucleobase overhang of deoxythymidine(dT) would have the following structure:

cgagaggcggacgggaccgTT
||||||||||||||
TTgctctccgcctgccctgqc

Antisense Strand (SEQ ID NO: 340)

Complement (SEQ ID NO: 341)

# RECEIVED CENTRAL FAX CENTER

ISIS PATENT DEPT

## AUG 2 9 2005

PTO/SB/21 (09-04) Approved for use through 07/31/2006, CMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid QMB control number. Application Number 10/672,866 TRANSMITTAL Filing Date 9/26/2003 First Named Inventor **FORM** C. Frank Bennett Art Unit 1635 Examiner Name Kimberly Chong (to be used for all correspondence after initial filing) Attorney Docket Number RTS-0242US.P1 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) **|** Pelition Amendment/Repty Petition to Convert to a Proprietary Information Provisional Application Power of Attorney, Revocation After Final Change of Correspondence Address Status Letter Affidavits/declaration(s) Other Enclosure(s) (please identify ~ Terminal Disclaimer Extension of Time Request below): Request for Refund Express Abandonment Request CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks RECEIVED Document(s) Reply to Missing Parts/ OIPE/IAP Incomplete Application
Reply to Missing Parts under 37 CFR 1.52 or 1.53 AUG 3 0 2005 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Isis Pharmaceuticals, Inc. Signature Printed name Colleen J. McKieman, Ph.D. Date Reg. No. 29,2005 48/570 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail\_in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature Date 29 Typed or printed name Laura Eames **2005** 

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete this including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, P.O. Box 1450, Asusandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.